• Business Wire

    Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced its results of operations and financial condition for the first quarter ended March 31, 2015. Provectus will also hold its quarterly business update conference call at 4 p.m. (EDT) today to provide a business update on